Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON 19 NOVEMBER 2025

References are made to the circular (the "**Circular**") of of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (百奧賽圖(北京)醫藥科技股份有限公司) (the "**Company**") incorporating, among others, the notice (the "**Notice**") of the 2025 first extraordinary general meeting (the "**EGM**"), both dated November 3, 2025. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board hereby announces that the EGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Wednesday, November 19, 2025 at 10:00 a.m.. The EGM was held in accordance with the requirements of the PRC Company Law and the Articles.

As at the date of the EGM, the total number of issued Shares of the Company was 399,398,420 (excluding treasury shares, if any), comprising 110,781,920 H Shares and 288,616,500 Domestic and Unlisted Shares, all of which entitled the Shareholders to attend the EGM and vote for or against or abstain from voting on the resolutions (the "**Resolutions**") proposed at the EGM. The Company did not hold treasury shares and no voting rights of treasury shares has been exercised at the EGM. The trustees of the Share Award Scheme holds an aggregate of 3,542,607 unvested Shares (comprising (i) the underlying Shares of the granted share awards which remain unvested; and (ii) such other Shares held for future grant of share awards) with voting rights attached (representing approximately 0.89% of the number of the issued Shares) had abstained from voting on any of the Resolutions at the EGM. To the best knowledge, information and belief of the Company, save as disclosed above, (i) there were no Shares entitling the holder to attend and abstain from voting in favor of the Resolutions proposed at the EGM as set out in rule 13.40 of the Listing Rules; (ii) no Shareholder was required under the Listing Rules to abstain from voting on the Resolutions proposed at the EGM; and (iii) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the Resolutions proposed at the EGM. All Resolutions were put to vote by way of poll.

A total of 12 Shareholders and their proxies holding an aggregate of 320,241,276 Shares with voting rights, representing 80.18% of the total number of the voting Shares attended the EGM. Dr. Shen Yuelei, the chairman of the Company, acted as the chairman of the EGM and presided over it. All the Directors, the Supervisors, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication. The EGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results are lawful and valid.

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and one Supervisor, were appointed as the scrutineer at the EGM for the purpose of vote-taking. The poll results of the EGM were as follows:

Special Resolutions		**Number of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the resolution relating to proposed Issue of A Shares (the "**Issue of A Shares**");	320,189,776 (99.98%)	51,500 (0.02%)	0 (0.00%)
2.	To consider and approve the resolution on authorizing the Board of Directors and persons authorized by it to fully handle relevant matters in connection with Issue of A Shares and listing on the Sci-Tech Board;	320,189,776 (99.98%)	51,500 (0.02%)	0 (0.00%)
3.	To consider and approve the resolution relating to proposed amendments to the Articles;	320,241,276 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To consider and approve the amendment to and/or adoption of each of the following rules:			
	i. the "Rules of Procedures of Shareholders' General Meeting"; and	320,241,276 (100.00%)	0 (0.00%)	0 (0.00%)
	ii. the "Rules of Procedures for the Board of Directors";	320,241,276 (100.00%)	0 (0.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
5.	To consider and approve the amendment to and/or adoption of each of the following systems by the Company:			
	i. the Working System for Independent Non-Executive Directors;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
	ii. the Measures for the Management of Connected Transactions;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
	iii. the Measures for the Management of External Guarantees;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
	iv. the Management System for Regulating Fund Transactions with Connected Parties;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
	v. the Measures for the Use and Management of Raised Funds;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
	vi. the Work System for Independent Non-Executive Directors on Annual Reports;	320,241,276 (100.00%)	0 (0.00%)	0 (0.00%)
	vii. the Measures for the Management of Outbound Investment;	319,714,776 (99.84%)	526,500 (0.16%)	0 (0.00%)
6.	To consider and approve the abolishment of the Supervisory Committee.	320,241,276 (100.00%)	0 (0.00%)	0 (0.00%)

As more than two-thirds of the votes were cast in favor of the special Resolutions numbered 1 to 4 above, and as more than half of the votes were cast in favor of the ordinary Resolutions numbered 5 to 6 above, all of the above Resolutions were duly passed at the EGM.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, 19 November, 2025

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.